지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2018.1
- 수록면
- 46 - 51 (6page)
이용수
초록· 키워드
오류제보하기
Purpose: Endocrine therapy is the preferred treatment for hormone receptor (HR)-positive metastatic breast cancer (MBC). We investigated the efficacy of combined aromatase inhibitor (AI) and luteinizing hormone-releasing hormone (LHRH) agonist in premenopausal patients with HR-positive MBC. Methods: We retrospectively analyzed the medical records of 21 HR-positive premenopausal MBC patients treated with combined AI and LHRH agonist therapy. Results: The median follow-up period was 32.9 months. The overall response rate was 47.6%, with three complete responses (14.3%) and seven partial responses (33.3%). Nine patients (42.9%) achieved stable disease lasting more than 6 months; thus, the clinical benefit rate was 90.4%. The median time to progression was 45.4 months. No patients experienced grade 3 or 4 toxicity. Conclusion: Combined AI and LHRH agonist treatment safely and effectively induced remission or prolonged disease stabilization, suggesting that this could be a promising treatment option for HR-positive premenopausal patients with MBC.
목차
등록된 정보가 없습니다.
참고문헌 (20)
참고문헌 신청
Torre LA / 2015 / Global cancer statistics, 2012 / CA Cancer J Clin 65:87~108
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) / 2005 / Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials / Lancet 365:1687~1717
Gennari A / 2005 / Survival of metastatic breast carcinoma patients over a 20-year period: a retrospective analysis based on individual patient data from six consecutive studies / Cancer 104:1742~1750
Stockler M / 2000 / Systematic reviews of chemotherapy and endocrine therapy in metastatic breast cancer / Cancer Treat Rev 26:151~168
Osoba D / 1995 / Health-related quality of life as a treatment endpoint in metastatic breast cancer / Can J Oncol 5(Suppl 1):47~53
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) / 2005 / Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials / Lancet 365:1687~1717
Gennari A / 2005 / Survival of metastatic breast carcinoma patients over a 20-year period: a retrospective analysis based on individual patient data from six consecutive studies / Cancer 104:1742~1750
Stockler M / 2000 / Systematic reviews of chemotherapy and endocrine therapy in metastatic breast cancer / Cancer Treat Rev 26:151~168
Osoba D / 1995 / Health-related quality of life as a treatment endpoint in metastatic breast cancer / Can J Oncol 5(Suppl 1):47~53
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Efficacy of an Aromatase Inhibitor Plus a Luteinizing Hormone-Releasing Hormone Agonist in Premenopausal Patients with Hormone Receptor-positive Metastatic Breast Cancer
대한임상종양학회 학술대회지
2015 .02
-
Role of Ovarian Function Suppression in Premenopausal Women with Early Breast Cancer
Journal of Breast Cancer
2016 .01
-
Durable Response of Androgen Receptor-Positive Male Breast Cancer to Goserelin
Journal of Breast Cancer
2019 .01
-
Survival Outcome of Combined GnRH Agonist and Tamoxifen Is Comparable to That of Sequential Adriamycin and Cyclophosphamide Chemotherapy Plus Tamoxifen in Premenopausal Patients with Lymph-Node–Negative, Hormone-Responsive, HER2-Negative, T1-T2 Breast Cancer
Cancer Research and Treatment
2016 .01
-
전이성 유방암의 호르몬 치료
대한내과학회지
2017 .06
-
Effect of Hormone Therapy on Long-term Outcomes of Patients with Human Epidermal Growth Factor Receptor 2-and Hormone Receptor-Positive Metastatic Breast Cancer: Real World Experience in China
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Bilateral Salpingo-oophorectomy Compared to Gonadotropin-Releasing Hormone Agonists in Premenopausal Hormone Receptor–Positive Metastatic Breast Cancer Patients Treated with Aromatase Inhibitors
Cancer Research and Treatment
2017 .01
-
Oncology Efficacy of Gonadotropin-Releasing Hormone Agonist in Hormone Receptor-Positive Very Young Breast Cancer Patients Treated with Neoadjuvant Chemotherapy
대한외과학회 학술대회 초록집
2018 .11
-
A pilot study of gonadotropin-releasing hormone agonist combined with aromatase inhibitor as fertility-sparing treatment in obese patients with endometrial cancer
Journal of Gynecologic Oncology
2019 .01
-
Efficacy of Letrozole as First-Line Treatment of Postmenopausal Women with Hormone Receptor–Positive Metastatic Breast Cancer in Korea
Cancer Research and Treatment
2017 .01
-
Aromatase Inhibition and Capecitabine Combination as 1<sup>st</sup> or 2<sup>nd</sup> Line Treatment for Metastatic Breast Cancer - a Retrospective Analysis
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Can chemotherapy be omitted for patients with N0 or N1 endocrine-sensitive breast cancer treated with gonadotropin-releasing hormone agonist and tamoxifen?
Annals of Surgical Treatment and Research
2023 .07
-
Concurrent Gonadotropin-Releasing Hormone Agonist Administration with Chemotherapy Improves Neoadjuvant Chemotherapy Responses in Young Premenopausal Breast Cancer Patients
Journal of Breast Cancer
2015 .01
-
Serum Cholesterol Level Changes during Gonadotropin-Releasing Hormone-Agonist Therapy in Premenopausal Female Patients with Breast Cancer
대한폐경학회지
2024 .08
-
Bone Mineral Density and Breast Cancer Risk Factors among Premenopausal and Postmenopausal Women - A Systematic Review
Asian Pacific journal of cancer prevention : APJCP
2016 .01
-
Change in Estradiol Levels among Premenopausal Patients with Breast Cancer Treated Using Leuprolide Acetate 11.25 Milligrams 3-Month Depot and Tamoxifen
Journal of Breast Cancer
2020 .01
-
Endometrial polyp surveillance in premenopausal breast cancer patients using tamoxifen
Obstetrics & Gynecology Science
2017 .01
-
Clinical Features of Male Breast Cancer: Experiences from Seven Institutions Over 20 Years
Cancer Research and Treatment
2016 .01
-
A comparative study of the clinical characteristics and outcomes of hormone receptor positive, HER2 negative breast cancer patients over 65 years old and under 65 years old patients
대한임상종양학회 학술대회지
2020 .07
-
Optimal Choice of Adjuvant Endocrine Therapy in Premenopausal Patients
대한외과학회 학술대회 초록집
2022 .11
이 논문의 저자 정보
최근 본 자료
댓글(0)
0